Next Article in Journal
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
Previous Article in Journal
Synthesis, Antiplasmodial, and Antileukemia Activity of Dihydroartemisinin–HDAC Inhibitor Hybrids as Multitarget Drugs
Previous Article in Special Issue
Identification of a Thyroid Hormone Derivative as a Pleiotropic Agent for the Treatment of Alzheimer’s Disease
 
 
Article

Article Versions Notes

Pharmaceuticals 2022, 15(3), 334; https://doi.org/10.3390/ph15030334
Action Date Notes Link
article xml file uploaded 9 March 2022 16:34 CET Original file -
article xml uploaded. 9 March 2022 16:34 CET Update -
article pdf uploaded. 9 March 2022 16:34 CET Version of Record https://www.mdpi.com/1424-8247/15/3/334/pdf-vor
article html file updated 9 March 2022 16:36 CET Original file -
article supplementary file uploaded. 9 March 2022 16:39 CET - https://www.mdpi.com/1424-8247/15/3/334#supplementary
article html file updated 9 March 2022 16:40 CET Update -
article xml file uploaded 23 March 2022 09:45 CET Update -
article xml uploaded. 23 March 2022 09:45 CET Update https://www.mdpi.com/1424-8247/15/3/334/xml
article pdf uploaded. 23 March 2022 09:45 CET Updated version of record https://www.mdpi.com/1424-8247/15/3/334/pdf
article html file updated 23 March 2022 09:46 CET Update -
article html file updated 1 August 2022 04:54 CEST Update https://www.mdpi.com/1424-8247/15/3/334/html
Back to TopTop